NRx Pharmaceuticals, Inc. (NRXP) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Wilmington, DE, United States. El CEO actual es Jonathan C. Javitt.
NRXP tiene fecha de IPO 2017-12-04, 2 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $43.56M.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
